StockData

Castle Biosciences vs NeoGenomics

CSTL and NEO side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CSTL and NEO compare

NeoGenomics is the larger company, worth 2.0 times as much as Castle Biosciences ($2.0B against $1.0B).

NeoGenomics grew revenue faster over the last twelve months (11.1% versus 9.8% for Castle Biosciences).

NeoGenomics keeps more of each dollar of sales as profit, with a net margin of −4.1% compared with −6.1% at Castle Biosciences.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCSTLNEO
Size and price
Market cap$1.0B$2.0B
Share price$32.98$15.25
Change, 1 year−1.4%47.5%
Change, 5 years−23.5%−58.4%
Beta (5Y)0.680.85
Employees8832,500
StockData Score
Total score1111
Valuation score23 (better)
Growth score24 (better)
Performance score33
Health score4 (better)1
Dividend score00
Valuation
P/S2.7×2.5× (better)
P/B2.1× (better)2.5×
P/FCF254×–
FCF yield0.39% (better)−1.4%
Fair value$34.22$19.80
Margin of safety3.6%23.0% (better)
Growth
Revenue growth (TTM)9.8%11.1% (better)
Revenue growth, 5Y average40.6% (better)10.4%
Profitability
Gross margin77.1% (better)44.8%
Operating margin−7.4%−6.3% (better)
Net margin−6.1%−4.1% (better)
FCF margin1.1% (better)−3.6%
Return on equity−4.9%−3.9% (better)
Return on invested capital−11.1%−4.6% (better)
Financial health
Debt / equity0.02 (better)0.47
Interest coverage−51.2×−15.2× (better)
Current ratio5.28 (better)3.53
Altman Z-score6.49 (better)2.30
Piotroski F-score44
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Buyback yield–−0.02%
Shareholder yield0.00% (better)−0.02%
Ownership
Held by institutions89.5%112%
Held by insiders1.9%1.5%
Insider net buying, 12 months−$18.4M−$717K (better)
Short interest, % of float7.0%10.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.